1) Isizaki T, Koizumi K, Ikemori R, Ishiyama Y, and Kushibiki E., Studies of prevalence of Japanese cedar pollinosis among the residents in a densely cultivated area. Ann Allergy, 1987. 58: 265-270.
2) Horiguchi S and Saito Y., Japanese Cedar Pollinosis in Nikko, Japan. Japanese Journal of Allergology, 1964. 13(1-2): 16-18, 74-75.
3) Konno A, Kubo N., Patient satisfaction with the second generation antihistamines in the treatment of pollinosis and improved awareness on medical consultation – choice of drugs based on a large-scale questionnaire survey in patients with pollinosis. Prog Med, 2008. 28: 2285–96.
4) Shamji MH, Ljorring C, Francis JN, Calderon MA, Larche M, Kimber I, et al., Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy. Allergy, 2012. 67: 217-226.
5) Durham SR, Walker SM, Varga EM, Jacobson MR, O’Brien F, Noble W, et al., Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med, 1999. 341: 468-475.
6) Matsuoka T, Shamji MH, Durham SR., Allergen immunotherapy and tolerance.Allergol Int, 2013. 62: 403-413.
7) Akdis M, Akdis CA., Mechanisms of allergen- specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. J Allergy Clin Immunol, 2014. 133: 621-631.
8) Calderon MA, Penagos M, Sheikh A, Canonica GW, Durham SR., Sublingual immunotherapy for allergic conjunctivitis: Cochrane systematic review and meta-analysis. Clin Exp Allergy, 2011. 41: 1263-1272.
9) Durham SR, Emminger W, Kapp A, de Monchy JG, Rak S, Scadding GK, et al.,SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol, 2012. 129: 717-725 e715.
10) Gotoh M, Yonekura S, Imai T, Kaneko S, Horikawa E, Konno A, et al., Long-Term Efficacy and Dose-Finding Trial of Japanese Cedar Pollen Sublingual Immunotherapy Tablet. J Allergy Clin Immunol Pract, 2019. 7(4): 1287-1297. e8
11) Durham SR, Creticos PS, Nelson HS, Li Z, Kaur A, Meltzer EO, et al., Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses. J Allergy Clin Immunol, 2016. 138(4): 1081-1088 e4.
12) Scadding GK, Brostoff J., Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. Clin Allergy, 1986. 16(5): 483‒491.
13) Okubo K, Gotoh M, Fujieda S, Okano M, Yoshida H, Morikawa H, et al., A randomised double-blind comparative study of sublingual immunotherapy for cedar pollinosis. Allergol. Int, 2008. 57: 265–275.
14) Wang M, Takeda K, Shiraishi Y, Okamoto M, Dakhama A, Joetham A, et al., Peanut-induced intestinal allergy mediated through a mast cell-IgE FcRI IL-13 pathway. J Allergy Clin Immunol, 2010. 126: 306-16.
15) Akdis M., Healthy immune response to allergens: T regulatory cells and more. Curr Opin Immunol, 2006. 18: 738–44.
16) Akdis M, Akdis CA., Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol, 2007. 119: 780–91.
17) Larche M, Akdis CA, Valenta R., Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol, 2006. 6: 761–71.
18) Bacher P, Scheffold A., The effect of regulatory T cells on tolerance to airborne allergens and allergen immunotherapy. J Allergy Clin Immunol, 2018. 142: 1697-1709.
19) Wachholz PA, Nouri-Aria KT, Wilson DR, Walker SM, Verhoef A, Till SJ, et al., Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokineratios. Immunology, 2002. 105: 56–62.
20) Bohle B, Kinaciyan T, Gerstmayr M, Radakovics A, Jahn-Schmid B, Ebner C., Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol, 2007. 120: 707-13.
21) Rosser EC, Mauri C., Regulatory B cells: origin, phenotype, and function.Immunity, 2015. 42: 607-12.
22) Shamji MH, Francis JN, Würtzen PA, Lund K, Durham SR, Till SJ., Cell-free detection of allergen-IgE cross-linking with immobilized phase CD23: inhibition by blocking antibody responses after immunotherapy. J Allergy Clin Immunol, 2013. 132: 1003-5, e1-4.
23) Flicker S, and R Valenta., Renaissance of the blocking antibody concept in type I allergy. Int. Arch. Allergy Immunol, 2003. 132: 13–24.
24) van Neerven, RJ, Knol EF, Ejrnaes A, and Würtzen PA., IgE mediated allergen presentation and blocking antibodies: regulation of T-cell activation in allergy. Int Arch Allergy, 2006. 141(2): 119-29.
25) Wachholz PA, Soni NK, Till SJ, Durham SR., Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol, 2003. 112: 915-22.
26) Reisinger J, Horak F, Pauli G, van Hage M, Cromwell O, Konig F, et al.,Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J Allergy Clin Immunol, 2005. 116: 347-54.
27) Oefner CM, Winkler A, Hess C, Lorenz AK, Holecska V, Huxdorf M, et al., Tolerance induction with T cell-dependent protein antigens induces regulatory sialylated IgGs. J Allergy Clin Immunol, 2012. 129: 1647-55.e13.
28) Gleich GJ., The late phase of the immunoglobulin E-mediated reaction: a link between anaphylaxis and common allergic disease? J Allergy Clin Immunol, 1982. 70: 160-9.
29) Scadding GW, Calderon MA, Bellido V, Koed GK, Nielsen NC, Lund K, et al., Optimization of grass pollen nasal allergen challenge for assessment of clinical and immunological outcomes. J Immunol Methods, 2012. 384: 25-32.
30) Francis JN, James LK, Paraskevopoulos G, Wong C, Calderon MA, Durham SR, et al., Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol, 2008. 121: 1120-5.e2.
31) Würtzen PA, Lund G, Lund K, Arvidsson M, Rak S, and Ipsen H., A double-blind placebo-controlled birch allergy vaccination study II: correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation. Clin. Exp. Allergy, 2008. 38: 1290–1301.
32) Johansen N, Gronager PM, Ipsen H, Stranzl T, Lund K., Characterization of a new method for quantitative determination of house dust mite allergen specific IgEblocking factor for monitoring allergy immunotherapy with SQ HDM SLIT-tablet. Allergy, 2016. 71: 118-272, ab321.
33) Fukano C, Ohashi-D K, Lund K, Nakao A, Masuyama K, Matsuoka T.,Establishment of enzyme-lnked immunosorbent facilitated antigen binding as abiomarker assay for Japanese cedar pollen allergy immunotherapy. J Pharmacol Sci, 2019. 140(3): 223-227.
34) Demeulemester C, Weyer A, Peltre G, Laurent M, Marchand F and David B., Thermoinactivation of human IgE: antigenic and functional modifications. Immnol, 1986. 57: 617-620.
35) Jarvis D, Zock JP, Heinrich J, Svanes C, Verlato G, Olivieri M, et al., Cat and dust mite allergen levels, specific IgG and IgG4, and respiratory symptoms in adults. J Allergy Clin Immunol, 2007. 119(3): 697-704.
36) Shamji MH, J.L.a.D.S., Serum Immunologic Markers for Monitoring Allergen-Specific Immunotherapy. Immunol Allergy Clin North Am, 2011. 31: 311-323.
37) Scadding GW, Shamji MH, Jacobson MR, Lee DI, Wilson D, Lima MT, et al., Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy, 2010. 40(4): 598-606.
38) Mothes N, Heinzkill M, Drachenberg KJ, Sperr WR, Krauth MT, Majlesi Y, et al., Allergen-specific immunotherapy with a monophospphoryl lipid A-adjuvanted vaccine reduced seasonally boosted IgE production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy, 2003. 33: 1198-1208.
39) Ejrnaes AM, Svenson M, Lund G, Larsen JN and Jacobi H., Inhibition of rBet v a-induced basophil histamine release with specific immunotherapy-induced serum IgG no evidence that FcRIIB signaling is important. Clin Exp Allergy, 2006. 36: 273-82.
40) Lambin P, Bouzoumou A, Murrieta M, Debbia M, Rouger P, Leynadier F, et al., Purification of human IgG4 subclass with allergen-specific blocking activity. J Immunol Methods, 1993. 165: 99-111.
41) Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker AM, Wilcock LK, et al., Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J. Immunol, 2004. 172: 3252–3259.
42) Willumsen N, Holm J, Christensen LH, Würtzen PA, and Lund K., The complexity of allergic patients' IgE repertoire correlates with serum concentration of allergen-specific IgE. Clin Exp Allergy, 2012. 42(8): 1227-36.
43) Holm J, Willumsen N, Würtzen PA, Christensen LH, and Lund K., Facilitated antigen presentation and its inhibition by blocking IgG antibodies depends on IgE repertoire complexity. J Allergy Clin Immunol, 2011. 127(4): 1029-37.
44) Christensen LH, Holm J, Lund G, Riise E, and Lund K., Several distinct properties of the IgE repertoire determine effector cell degranulation in response to allergen challenge. J Allergy Clin Immunol, 2008. 122(2): 298-304.
45) Zhao D, Lai X, Tian M, Jiang Y, Zheng Y, Gjesing B, et al., The Functional IgE-Blocking Factor Induced by Allergen-Specific Immunotherapy Correlates with IgG4 Antibodies and a Decrease of Symptoms in House Dust Mite-Allergic Children. Int Arch Allergy Immunol, 2016. 169(2): 113-20.